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Summary Using 31P NMR spectroscopy, changes in tumour metabolic status were studied in a transplanted
rat fibrosarcoma following the administration of vasodilators. Mean Arterial Blood Pressure (MABP) was
monitored simultaneously. Two vasodilators were studied, prazosin and CGRP, which altered the NMR
parameters Pi/uP, iNTP,Pi, PCr/Pi and PME/Pi in a dose dependent manner. There was a good correlation
between the various NMR papameters; for analysis, Pi/ulP was used for convenience. With increasing doses of
vasodilator, Pi/ulP increased and the MABP decreased. Reduction in pHNMR showed a correlation with
decreasing MABP following the administration of prazosin but not after CGRP.
Both prazosin and CGRP produced changes in 31P NMR spectra consistent with a reduction in tumour
blood flow. The results for prazosin and CGRP were comparable and showed a 15-20% increase in Pi/ulP for
a 20% reduction in MABP. These results were compared with those from hydralazine. With hydralazine an
acceptable reduction in blood pressure (up to -25%) has little effect and may even alter NMR parameters
consistent with an increase in blood flow, a reduction of 140% is required for a significant decrease in flow.
Both prazosin and CGRP are shown to be far more effective than hydralazine in causing tumour hypoxia at
a clinically acceptable reduction in blood pressure. CGRP may be the more suitable for clinical use because of
its short half life, its capability to achieve controlled hypotension and the relatively few side effects associated
with its use.
Selective reduction in tumour blood flow and the consequent
increase in hypoxia could have several advantages in cancer
treatment, for example in combination with drugs which are
selectively toxic to hypoxic cells (Brown, 1987; Chaplin &
Acker, 1987; Stratford et al., 1989; Bremner et al., 1990). It
might also be an advantage in treatment by hyperthermia,
resulting in higher tumour temperatures (Babbs et al., 1982)
and more uniform heating together with increased tumour
sensitivity resulting from decreased nutrient delivery and
reduced pH (Gerweck et al., 1979; Horsman et al., 1989).
The potential for selective manipulation of tumour blood
flow depends on differences in vasculature between tumours
and normal tissues. Tumours are thought to have long,
tortuous, leaky vessels with frequent A-V shunts, lack of
smooth muscle and probably no innervation. Interstitial pres-
sure tends to be high due to leaky vessels (Wiig et al., 1982)
and lack of lymph drainage (see Reinhold & Endrich, 1986
for review). The response of the vasculature of a tumour to a
vasodilator is likely to be different from that of a normal
tissue for two reasons (Chan et al., 1984). One is that the
tumour arterioles may react minimally or not at all to the
vasoactive stimuli so that vasodilation elsewhere results in
'stealing' of blood from the tumour. The second results from
the normally high tumour interstitial fluid pressure so that
any reduction in capillary hydrostatic pressure may lead to
tumour vascular collapse leading to flow stasis or even rever-
sal (Chaplin et al., 1987; Trotter et al., 1988; Trotter et al.,
1989).
The most successful attempts to reduce tumour blood flow
has been by the administration of hydralazine, a directly
acting vasodilator (Babbs et al., 1982). This has been shown
to decrease tumour blood flow in experimental animals and
also to potentiate the action of bioreductive compounds and
hyperthermia (Brown, 1987; Chaplin et al., 1987; Horsman et
al., 1989). However, to achieve these effects with hydralazine,
a substantial reduction in blood pressure is required, which is
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likely to limit the clinical use of hydralazine as a modifier of
tumour blood flow (Okunieff et al., 1989; Tozer et al., 1990).
For a reasonable, clinically acceptable reduction in blood
pressure, hydralazine has even been shown to cause an in-
crease in tumour blood flow (Kalmus et al., 1990; Rowell et
al., 1990). A further disadvantage of hydralazine is its long
half life (Gross, 1977). Clearly, there is a need to investigate
drugs which could be of greater therapeutic benefit.
Information related to tumour oxygenation and perfusion
status can be obtained from changes in bioenergetic status
using 31P Magnetic Resonance Spectroscopy (Evelhoch et al.,
1986; Rofstad et al., 1989). This technique has been used as a
non-invasive means of monitoring tumour metabolic status
following the administration of vasodilators hydralazine and
prostacyclin (Okunieff et al., 1989; Bhujwalla et al., 1990a;
Tozer et al., 1990). Recently a direct relationship between
tumour metabolic status and blood flow has been demon-
strated (Bhujwalla et al., 1990b). In the present study, we
have used 31P MRS to obtain information on tumour blood
flow by monitoring changes in tumour metabolism following
administration of various vasoactive compounds. Blood pres-
sure was monitored simultaneously, since this falls substan-
tially following administration of vasodilators. The results
from two vasodilators, prazosin and CGRF, are reported.
Prazosin is a quinazoline derivative which acts by competitive
blockade of post-synaptic ol-adrenergic receptors. Calcitonin
gene-related peptide (CGRP) is an endogenously occurring
peptide (Rosenfeld et al., 1983; Morris et al., 1984), which
acts by binding to its receptors in the vessel wall (Lundberg
et al., 1985). When given intravenously CGRP is one of the
most potent vasodilators known (Brain et al., 1985; Struthers
et al., 1986). It has the advantage of a short half life (Ben-
jamin et al., 1987). The mechanism of action of each of these
compounds is different from that of hydralazine, which acts
by directly relaxing the arteriolar smooth muscle.
Materials and methods
Tumour model
A transplanted rat fibrosarcoma, designated LBDS,, was
used for these experiments. The tumour arose spontaneously
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in the flank of a male BD9 rat and was serially transplanted.
Further details of these tumours may be found elsewhere
(Tozer & Morris, 1990). Only early generation transplants
were used. Tumour pieces 1-2mm', taken from a previous
generation isotransplant were implanted subcutaneously into
the right flanks of 10-12 week old BD9 rats. The rats were
then returned to their cages and housed in a temperature
controlled and light-cycled room. They were fed on normal
rat chow and water ad libitum. It took an average time of
30 ± 4 days for the tumours to reach 15-20 mm in diameter,
at which size they were used for experiments.
the magnet. The rat was placed on two plastic tissue culture
flasks containing recirculating warm water to maintain core
temperature at 37°C. It was positioned so that its tumour
hung vertically downwards between the two culture flasks
and rested on the surface coil. A baseline spectrum was
accumulated over a period of 20 min, following which either
prazosin or CGRP was injected via the tail vein catheter
without disturbing the position of the rat in the magnet.
Control rats were injected with 0.5 ml of saline. Spectra were
accumulated for at least 80 min following prazosin or water
and for up to 40 min following CGRP. Blood pressure was
monitored throughout.
Drugs used
In order to restrain the animals for NMR spectroscopy, they
were anaesthetised with a combination of fentanyl citrate
(0.315 mg kg-'), fluanisone (10 mg kg-') 'Hypnorm' (Crown
Chemical Co.) and midazolam (5 mg kg-') 'Hypnovel'
(Roche).
Prazosin (Sigma Chemical Co) was freshly dissolved in
water to give an iso-volume of 0.5 ml for various doses and
injected intravenously in bolus doses of 0.5, 1.0 and 1.5 mg
kg-' rat body weight.
Rat calcitonin gene-related peptide 'CGRP' (Peninsula
Lab) was dissolved in distilled, deionised water containing
0.001% (v/v) acetic acid and 0.1% (w/v) bovine serum
albumin, and stored at -70°C (Zaidi et al., 1989). For
intravenous injection, the mixture was re-dissolved in saline,
to give a constant injection volume of 0.5 ml for various
doses. CGRP was injected in bolus doses of 300 pmol (5.8 pg
kg-'), 600pmol (10.8pgkg-1), I nmol (20.2fgkg-') and
2 nmol (38.8fig kg-').
Spectroscopy
31P spectra were obtained on a 1.89T Oxford Research
Systems TMR-32 spectrometer. A range of radiofrequency
surface coils was used, the size (1-2 cm diameter) being
chosen to fit closely around the tumour. The magnetic field
was shimmed to obtain a H20 resonance with a maximum
linewidth of40 Hz. Experimental parameters included a spec-
tral width of 2 KHz, 900 pulse with a pulse length of 10fis,
pulse repetition time of 2 s, 2048 data points and 300 or 600
averaged free induction decays. Data processing involved
exponential line broadening of 15 Hz. Broad spectral lines
were removed by spectral deconvolution (Tozer et al., 1989).
Peak areas were calculated by a computer program which
allowed operator definition of the baseline and peak limits.
No assumptions were made about the peak shapes in the
analysis of spectra. However there could be a systematic
error from small signals due to peak overlap. This error
would be significant only if the area of the peak were con-
siderably different from that of neighbouring peaks. For
example if the area the inorganic phosphate peak were 2-fold
greater than that of the neighbouring peaks, it would be
underestimated by approximately 10%. Consequently
changes observed in the spectra following treatment with
vasodilators would be slightly underestimated. Non-syste-
matic error in estimating the peak area would have been of
the order of 10%, given the signal-to-noise ratio obtained in
the collection of spectra.
Bloodpressure measurements
Mean arterial blood pressure was monitored using a Gould
P23XL physiological pressure transducer connected to a
Gould RS3200 recorder (see below).
Experimentalprotocol
The rats were anaesthetised and polythene catheters contain-
ing heparinised normal saline were implanted into a tail vein
and tail artery. The tail artery catheter was connected to the
pressure transducer by a sufficient length of pressure tubing
to monitor the changes whilst the rat was within the bore of
Data analysis
The results given in both the text and figures are means and
standard errors for the given number of rats.
Results
A typical 31P NMR spectrum from a tumour is shown in
Figure la together with sequential spectra following an intra-
venous bolus injection of 600 pmol CGRP. The MABP
recorded simultaneously is shown in Figure lb. The principal
change in NMR spectrum was an increase in the amplitude
of the Pi peak, which was maximal in the first 10 min period,
whilst the blood pressure was at its minimum. With CGRP
there was a fairly rapid recovery of blood pressure, with Pi,
PCr and NTP peaks returning to control values more slowly.
Following prazosin, the changes in MRS parameters and
reduction in MABP were not reversed during the 80min
period ofstudy, consistent with the long half life ofthis drug.
With both prazosin and CGRP, the reduction in MABP
and corresponding increase in Pi/ZP were dose dependent.
Thus an inverse relationship was found between decreasing
MABP and increasing Pi/tP with escalating doses of vaso-
dilator, as shown in Figure 2 for CGRP. A similar result was
found for prazosin.
NMR parameters other than Pi/XP, i.e. PNTP/Pi, PCr/Pi
and PME/Pi were also recorded. PNTP/Pi and PCr/Pi show-
ed a good correlation with Pi/l:P as shown in Figure 3a and
b. Tables I and II show that the parameters Pi/ulP, PNTP/Pi,
PCr/Pi and PME/Pi were all correspondingly altered as a
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Figure 1 A, Sequential 31P NMR spectra from a rat fibrosar-
coma following the administration of 600 pmol CGRP. a, before
drug; b, 5 min; c, 15 min; d, 25 min after the injection of CGRP.
PME = Phosphomonoesters; Pi = Inorganic phosphate; PDE =
Phophodiesters; PCr = Phosphocreatine; yNTP = y nucleotide
triphosphate; aNTP = a nucleotide triphosphate; JINTP = p
nucleotide triphosphate. B, A simultaneously recorded trace of
MABP from the same study. Dark vertical line represents the
time of injection of the drug.MODIFICATION OF TUMOUR BLOOD FLOW BY CGRP 685
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Table I Effects of different doses ofprazosin on NMR parameters
Dose PiulP PNTP/Pi PCr/Pi PME/Pi
Control 102±13 92± 12 95± 10 114±09
0.5 mgkg-' 123±02 71±12 77±08 87±11
1.0 mg kg-' 148±09 60± 13 65±10 85± 16
1.5 mgkg-' 167±25 56±07 57±06 87±03
Figure are percentages. Values are from the data collected 50 min
after the administration of prazosin. Results are mean± s.e.m. from
three animals in each group.
-80 0m
2
-70
-60
Figure 2 Pi/uP and MABP followed as a function of dose of
CGRP. Each point represents mean for three animals. -0-
Pi/uP, -*- MABP.
1.0-
Table II Effects of different doses of CGRP on NMR parameters
Dose PiulP PNTP/Pi PCr/Pi PME/Pi
Control 106±07 93±09 101±12 104±05
300pmol 116±14 88± 14 102±22 88± 14
600pmol 126±06 79±05 78±00 80±07
1 nmol 140±09 66±13 56±11 69±05
2 nmol 142±17 48±03 57±07 79±14
Figures are percentages. Values are from the data collected 5 or
10min after the administration of CGRP. Results are mean±s.e.m.
from three animals in each group.
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Figure 4 Per cent change in Pi/£P and MABP as a function of
time following a dose of prazosin of 1 mg kg-'. Blood pressure is
averaged over a period of 20 min. Each point represents
mean+±s.e.m. from three animals. 0 , Pi/P; * , MABP.
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Figure 3 A, Correlation between NMR param
PCr/Pi following injection of two vasodilato
represents a mean from three animals. r = 0.66.
CGRP. B, Correlation between NMR parame
PNTP/Pi following injection of two vasodilatc
represents a mean from three animals. r = 0.44. 1
CGRP.
function of dose of prazosin or CGRP. No significant change
was observed in these parameters in control animals treated
with saline. Since these parameters are all interdependent, it
was decided to concentrate the analysis of Pi/£P for con-
venience.
The time course of changes of Pi/£P and blood pressure
following an injection of 1 mg kg-' prazosin is shown in
Figure 4. It is seen that following injection, there was a
steady fall in MABP with a corresponding increase in Pi/uLP.
At 70 min both were still changing. The response of Pi/XP
and MABP following administration of a bolus dose of
2 nmol CGRP is shown in Figure 5. In this case it can be
seen that there was a rapid fall in MABP with a correspond-
1.8 2.0 ing rapid increase in Pi/LP. However, the return towards
normal of MABP began after a few minutes, whereas Pi/uP
recovered more slowly. In all these studies the rats were
eters Pi/uP and anaesthetised by a combination of hypnorm and hypnovel.
)rs. Each point This anaesthetic slightly reduces the blood pressure (Field &
0, Prazosin;*, Burney, unpublished). However, any interactions between the
,ters Pi/LP and vasodilators and the anaesthetic are not known.
Drs. Each point
0, Prazosin; *,
Discussion
There is a strong evidence that 31P MRS can detect changes
in tumour bioenergetics brought about by changes in tumour
oxygenation and perfusion. For example, Evelhoch et al.
(1986), using in situ photon activation-50 decay measure-
ments and 31P NMR spectroscopy, showed a positive correla-
tion between '5O perfusion and NTP/Pi and PCr/NTP ratios.
A positive correlation was also observed between declining
mean tissue P02 and NTP/Pi, PCr/Pi, PME/Pi, PDE/Pi and
pHRNMR with increasing tumour size in a murine fibrosar-
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Figure 5 Per cent change in Pi/lP and MABP as a function of
time following a dose of 2 nmol CGRP. Blood pressure is
averaged over a period of 10 min. Each point represents
mean ± s.e.m. from three animals. , Pi/l:P; -*-, MABP.
coma (Vaupel et al., 1989). Rofstad et al. (1989) and
Mueller-Klieser et al. (1990) have both reported a decreasing
tumour bioenergetic status together with a decreasing HbO2
saturation levels as measured by cryospectrophometry. More
recently Bhujwalla et al. (1990b) have also shown a direct
correlation between PNTP/Pi and tumour blood flow.
The most effective vasodilator reported to cause hypoxia in
experimental tumours appears to be hydralazine which acts
directly on smooth muscle (Babbs, 1982; Voorhees & Babbs,
1982; Brown, 1987; Chaplin & Acker, 1987; Horsman et al.,
1989; Stratford et al., 1989). The effect results either from
diversion of blood away from the tumour to the normal
tissues termed the 'steal phenomenon' or from the reduction
in systemic blood pressure, leading to vascular collapse
(Chaplin et al., 1987; Trotter et al., 1989). Tozer et al. (1990)
used 31P NMR to demonstrate that hydralazine is more
effective than prostacyclin in causing changes consistent with
reduction in tumour perfusion for a given reduction in blood
pressure.
Hydralazine can cause almost complete radiobiological
hypoxia in tumours but this requires high doses of
drugs resulting in a massive and clinically unacceptable
reduction in blood pressure (Okunieff et al., 1989; Tozer et
al., 1990). At lower doses of hydralazine (0.1 mg kg-' in
rodents), resulting in a clinically acceptable reduction in
blood pressure (up to :25%), laser doppler flow studies
show that tumour blood flow may actually be improved
(Kalmus et al., 1990). Some NMR studies also show changes
consistent with improved tumour blood flow following lower
doses of hydralazine (Okunieff et al., 1989; Tozer et al.,
1990). These experimental results are consistent with the
clinical studies of Rowell et al. (1990) who showed an in-
crease in tumour blood flow measured by Single Photon
Emission Computed Tomography (SPECT) in patients given
oral hydralazine.
Taken together these results show that at a clinically
acceptable reduction in blood pressure, hydralazine may even
cause an improved blood flow and only with a clinically
unacceptably large reduction in blood pressure is blood flow
reduced. In addition, hydralazine has a fairly long half life
(Gross, 1977). Clearly hydralazine is unlikely to be ofclinical
use in reducing tumour blood flow and more effective vaso-
dilators are needed for this purpose.
Prazosin and CGRP both produced changes in NMR spec-
tra consistent with a reduction in tumour blood flow for
much smaller reduction in blood pressure than with hydra-
lazine. The relative effectiveness of these compounds is dem-
onstrated in Figure 6, in which an injection resulting in a
20% drop in MABP, causes at least a 15% increase in Pi/ulP.
In contrast, a similar drop in blood pressure with hydralazine
leads to a 15% decrease in Pi/IP, consistent with an increase
in blood flow. With hydralazine it is necessary to give suffi-
cient dose to cause at least a 30-40% reduction in blood
%MABP
Figure 6 Per cent change in Pi/lP plotted as a function of per
cent reduction in MABP. Each point represents mean from three
or four animals. Blood pressure is averaged over a period of
10 min. Curve A is for prazosin and CGRP. Curve B is for
hydralazine. The curves were drawn by eye. 100% Pi/MP is the
reference point, anything above 100% implies a reduction in
blood flow and anything below 100% implies an improvement.
M, Hydralazine; 0, Prazosin; +, CGRP.
pressure to achieve a significant increase in Pi/uP.
In control animals treated with saline, the variation in the
NMR parameters was relatively small. As seen in Tables I
and II, the variation in the ratios Pi/lP, ,NTP/Pi, PCr/Pi
and PME/Pi was of the order of 2-8%. The variability in
the area of the same individual peak in spectra collected from
the same control tumour ranged between 4-12%. The exper-
imental design, such that the rat was not moved within the
magnet throughout the course of the experiment, the drug
being administered remotely, ensured that any change in
spectrum was due solely to the administration of the drug.
The use of anaesthetics to immobilise the rats during the
procedures is almost certainly less perturbing than the
methods to forcibly restrain them. The anaesthetic used was
a combination of a morphine type analgesic, fentanyl; a
neuroleptic of butyrophenene group, fluanisone; and a benzo-
diazepine, midazolam; all mediating their effect through the
centra nervous system. This combination anaesthetic was
chosen because it has the advantage over other commonly
used anaesthetics (such as pentobarbital, ketamine, mor-
phine, halothane and enflurane), of not increasing the peri-
pheral vascular resistance, conferring better stress protection
and preserving tissue perfusion (Skolleborg et al., 1990).
Although no interaction between this combination anaes-
thetic and the different vasodilators used in this study has
been documented, it seems unlikely that any such interaction
would occur between such centrally acting anaesthetic agents
and the tested vasoactive compounds which mediate their
effect through specific receptors. Furthermore, this combina-
tion anaesthetic has little or no effect on the release of
corticosteroids, which play an important role in central
haemodynamics and an interaction with the hypothalamic-
hypophyseal-cortical axis also seems unlikely.
Whereas, midazolam has little or no effect on various
haemodynamic parameters, fentanyl and fluanisone do
decrease the mean aortic blood pressure and increase the
cardiac output, although the reduction in blood pressure is
less than that produced by the other commonly used anaes-
thetics e.g. pentobarbitone, ketamine or diazepam (Cullen &
Walker, 1986). The aim of the study was to relate changes in
NMR parameters to changes in blood pressure. If there were
any effect of the anaesthetic it would almost certainly be
confined to causing a small additional reduction in blood
pressure and would be a common factor throughout, includ-
ing all similar studies with hydralazine, which have been used
for comparison to the effects of CGRP and prazosin. Any
effect of the anaesthetic would therefore not alter the con-
clusions.
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Table III Plasma and biological half-lives of three vasodilators in
man
Half-life in man
Drug Plasma Biological
Hydralazine 4 h 30 h
Prazosin 2-3h 10-12h
CGRP 9 min 19 min
Prazosin may not be suitable for clinical use as a modifier
of tumour blood flow because of its long half life (see Table
III). The hypotensive effects may last for up to 10-12 h
(Stanaszek et al., 1983). Faintness and dizziness have been
reported to occur in 50% of patients receiving this drug.
Severe orthostatic hypotension is less common and is attri-
buted to the 'first dose effect' (Rudd & Blaschke, 1985).
One of the limitations for the clinical use of CGRP might
be the sudden reduction in blood pressure during the first few
minutes following the injection of a bolus dose. This may be
particularly harmful to elderly patients. However, it has been
shown that CGRP can be administered safely by infusion to
achieve controlled hypotension (Struthers et al., 1986).
CGRP has a short plasma and biological halflife in man (see
Table III). This may be a very effective method of adminis-
tration since the effects on metabolism are more prolonged
than the reduction in blood pressure (Figure 5). Lack of
tachyphylaxis and other side effects associated with prazosin
and hydralazine, make CGRP the more favourable for clini-
cal use.
The increase in tumour blood flow following low doses of
hydralazine suggested by a decrease in Pi/ZP and by other
techniques (Kalmus et al., 1990; Rowell et al., 1990) can be
explained by increased perfusion pressure occurring as a
result of reflex sympathetic stimulation in the presence of
little vasodilatation (Maekawa et al., 1984). Prazosin blocks
the action of nor-epinephrine by post-synaptic receptor
blockade and subsequently decreases its further release
through negative feed back control (Stanaszek et al., 1983).
CGRP causes sympathetic stimulation (Fisher et al., 1983),
increasing the nor-epinephrine release by almost 2-fold.
Although the mechanism of action of these drugs is far from
fully understood, there appears to be a similarity in the mode
of action of prazosin and CGRP, both being receptor
mediated, in contrast to hydralazine which is known to cause
arteriolar vasodilatation by direct relaxation of smooth mus-
cle (Ablad, 1963). Whether this difference in the mode of
action is the cause ofprazosin and CGRP being substantially
more effective than hydralazine in modifying tumour blood
flow for a given reduction in MABP, remains speculative. It
is plausible however, that compounds with a receptor mediat-
ed mode of action, because of sensitive vasomotor control,
preferentially cause vascular collapse and flow stasis, thus
rendering tumours hypoxic for small reduction in blood
pressure. In contrast, diversion of blood by the 'steal'
phenomenon to cause hypoxia probably requires a greater
reduction in systemic blood pressure.
In conclusion, two vasodilators, prazosin and CGRP, have
been shown to produce changes in MRS parameters consis-
tent with a reduction in tumour blood flow at a substantially
smaller reduction in mean arterial blood pressure than hydra-
lazine. CGRP has the greater potential for clinical use
because it has a short half life and a lower probability of
causing side effects. Studies are in progress using PET to
monitor changes in human tumour blood flow following
administration of CGRP. There is however a need to under-
stand better the mechanism of action of these drugs in the
context ofpathophysiology oftumour vasculature, ifthey are
to be used to maximal effect.
This work was supported by a grant from Medical Research Council
and a grant from Cancer Research Campaign.
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